SEARCH

SEARCH BY CITATION

References

  • 1
    Iozzo RV & San Antonio JD (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108, 349355.
  • 2
    Kjellen L & Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60, 443475.
  • 3
    Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J & Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729777.
  • 4
    Capila I & Linhardt RJ (2002) Heparin–protein interactions. Angew Chem Int Ed Engl 41, 391412.
  • 5
    Lindahl U & Li JP (2009) Interactions between heparan sulfate and proteins – design and functional implications. Int Rev Cell Mol Biol 276, 105159.
  • 6
    Whitelock JM & Iozzo RV (2005) Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105, 27452764.
  • 7
    Fransson LA, Belting M, Cheng F, Jonsson M, Mani K & Sandgren S (2004) Novel aspects of glypican glycobiology. Cell Mol Life Sci 61, 10161024.
  • 8
    Cole GJ & Halfter W (1996) Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 3, 359371.
  • 9
    Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609652.
  • 10
    Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12, 8998.
  • 11
    Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L & Kovalszky I (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12, 173186.
  • 12
    Fuster MM & Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5, 526542.
  • 13
    Sanderson RD & Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25, 149159.
  • 14
    Lind T, Tufaro F, McCormick C, Lindahl U & Lidholt K (1998) The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273, 2626526268.
  • 15
    McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP & Tufaro F (1998) The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19, 158161.
  • 16
    Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR & Shridhar V (2003) Loss of Hsulf-1up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278, 2310723117.
  • 17
    Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR & Shridhar V (2004) HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23, 14391447.
  • 18
    Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R & Sanderson RD (2005) HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280, 4006640073.
  • 19
    Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ & Parish CR (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5, 803809.
  • 20
    Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA & Bohlen P (1999) Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 261, 183187.
  • 21
    Toyoshima M & Nakajima M (1999) Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 274, 2415324160.
  • 22
    Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I et al. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5, 793802.
  • 23
    Ilan N, Elkin M & Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 20182039.
  • 24
    Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I & Ilan N (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49, 207210.
  • 25
    Vreys V & David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11, 427452.
  • 26
    Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I & Li JP (2009) Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 4, e5181.
  • 27
    Zcharia E, Metzger S, Chajek-ShaulL T, Aingorn H, Elikn M, Friedmann Y, Weinstein T, Jin-Ping L, Lindahl U & Vlodavsky I (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18, 252263.
  • 28
    Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S, Kleinman HK, Vlodavsky I & Elkin M (2005) Heparanase regulates murine hair growth. Am J Pathol 166, 9991008.
  • 29
    Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N et al. (2005) Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 19, 211221.
  • 30
    Casu B, Vlodavsky I & Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36, 195203.
  • 31
    Vlodavsky I, Ilan N, Naggi A & Casu B (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13, 20572073.
  • 32
    Ogren S & Lindahl U (1975) Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 250, 26902697.
  • 33
    Thunberg L, Backstrom G, Wasteson A, Robinson HC, Ogren S & Lindahl U (1982) Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta-d-glucuronidases. J Biol Chem 257, 1027810282.
  • 34
    Nakajima M, Irimura T, DiFerrante D, DiFerrante N & Nicolson GL (1983) Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B 16 melanoma sublines. Science (Wash DC) 220, 611613.
  • 35
    Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y & Schirrmacher V (1983) Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 43, 27042711.
  • 36
    Vokes EE, Weichselbaum RR, Lippman SM & Hong WK (1993) Head and neck cancer. N Engl J Med 328, 184194.
  • 37
    Ford AC & Grandis JR (2003) Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25, 6773.
  • 38
    Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V & Shedd DP (1987) Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154, 439442.
  • 39
    Zbaren P & Lehmann W (1987) Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113, 762764.
  • 40
    Baraz L, Haupt Y, Elkin M, Peretz T & Vlodavsky I (2006) Tumor suppressor p53 regulates heparanase gene expression. Oncogene 25, 39393947.
  • 41
    Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA et al. (2005) Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11, 10281036.
  • 42
    Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA et al. (2005) Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 24, 67656772.
  • 43
    Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I & Ben-Yehuda D (2003) Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22, 77377749.
  • 44
    Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N & Vlodavsky I (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8, 10551061.
  • 45
    Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I & Nagler R (2006) Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 8, 879884.
  • 46
    Nagler R, Ben-Izhak O, Cohen-Kaplan V, Shafat I, Vlodavsky I, Akrish S & Ilan N (2007) Heparanase up-regulation in tongue cancer: tissue and saliva analysis. Cancer 110, 27322739.
  • 47
    Leiser Y, Abu-El-Naaj I, Sabo E, Akrish S, Ilan N, Peled M & Vlodavsky I (2010) The prognostic value of heparanase expression and cellular localization in oral cancer. Head Neck, in press.
  • 48
    Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I & Ben-Izhak O (2006) Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 49, 188193.
  • 49
    El-Assal ON, Yamanoi A, Ono T, Kohno H & Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7, 12991305.
  • 50
    Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA & Xu X (2002) Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132, 326333.
  • 51
    Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I et al. (2002) Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Modern Pathol 15, 593598.
  • 52
    Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I & Abramovitch R (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118, 16091617.
  • 53
    Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I & Sherman Y (2006) Spatial and temporal heparanase expression in colon mucosa throughout the adenoma–carcinoma sequence. Modern Pathol 19, 878888.
  • 54
    Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ et al. (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105, 13031309.
  • 55
    Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I & Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63, 77337741.
  • 56
    Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I & Elkin M (2008) Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 14, 668676.
  • 57
    Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I & Vlodavsky I (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15, 16611663.
  • 58
    Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I & Ilan N (2004) Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279, 2353623541.
  • 59
    Edovitsky E, Elkin M, Zcharia E, Peretz T & Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96, 12191230.
  • 60
    Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D & Vlodavsky I (1988) A heparin-binding angiogenic protein – basic fibroblast growth factor – is stored within basement membrane. Am J Pathol 130, 393400.
  • 61
    Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J & Klagsbrun M (1987) Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84, 22922296.
  • 62
    Ben-Zaken O, Gingis-Velitski S, Vlodavsky I & Ilan N (2007) Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 361, 829834.
  • 63
    Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang X, Zheng X, Jiang H, Mikkelsen T & Chopp M (2008) Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells. J Exp Clin Cancer Res 27, 23.
  • 64
    Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I & Doweck I (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123, 25662573.
  • 65
    Alitalo K & Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219227.
  • 66
    Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I & Ilan N (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68, 1007710085.
  • 67
    Iozzo RV & Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small-leucine rich proteoglycans. FEBS J 277, 38643875.
  • 68
    Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE & Parish CR (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39, 1565915667.
  • 69
    Beauvais DM & Rapraeger AC (2004) Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2, 3.
  • 70
    Tkachenko E, Rhodes JM & Simons M (2005) Syndecans: new kids on the signaling block. Circ Res 96, 488500.
  • 71
    Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I & Ilan N (2005) Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 280, 2045720466.
  • 72
    Haskell MD, Slack JK, Parsons JT & Parsons SJ (2001) c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem Rev 101, 24252440.
  • 73
    Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I & Ilan N (2009) Structure–function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 69, 17581767.
  • 74
    Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A & Steinkuhler C (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43, 18621873.
  • 75
    Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, Peretz T & Vlodavsky I (2005) Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280, 1356813575.
  • 76
    Lai NS, Simizu S, Morisaki D, Muroi M & Osada H (2008) Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase. Exp Cell Res 314, 28342845.
  • 77
    Simizu S, Suzuki T, Muroi M, Lai NS, Takagi S, Dohmae N & Osada H (2007) Involvement of disulfide bond formation in the activation of heparanase. Cancer Res 67, 78417849.
  • 78
    Fux L, Ilan N, Sanderson RD & Vlodavsky I (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34, 511519.
  • 79
    Cooper TA, Wan L & Dreyfuss G (2009) RNA and disease. Cell 136, 777793.
  • 80
    Tazi J, Bakkour N & Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta 1792, 1426.
  • 81
    Nasser NJ, Avivi A, Shushy M, Vlodavsky I & Nevo E (2007) Cloning, expression, and characterization of an alternatively spliced variant of human heparanase. Biochem Biophys Res Commun 354, 3338.
  • 82
    Sato M, Amemiya K, Hayakawa S & Munakata H (2008) Subcellular localization of human heparanase and its alternative splice variant in COS-7 cells. Cell Biochem Funct 26, 676683.
  • 83
    Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O, Shemesh R, Ayalon-Sofer M, Ilan N & Vlodavsky I (2009) A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 24, 12391248.
  • 84
    Basche M, Gustafson DL, Holden SN, O’Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR et al. (2006) A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12, 54715480.
  • 85
    Fairweather JK, Hammond E, Johnstone KD & Ferro V (2008) Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg Med Chem 16, 699709.
  • 86
    Ferro V, Hammond E & Fairweather JK (2004) The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4, 693702.
  • 87
    Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL et al. (2008) A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26, 8994.
  • 88
    Kelly T, Miao H-Q, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F et al. (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63, 87498756.
  • 89
    Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M et al. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109, 49144923.
  • 90
    Sanderson RD, Yang Y, Suva LJ & Kelly T (2004) Heparan sulfate proteoglycans and heparanase – partners in osteolytic tumor growth and metastasis. Matrix Biol 23, 341352.
  • 91
    Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A & Borset M (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388392.
  • 92
    Theocharis AD, Skandalis SS, Tzanakakis GN & Karamanos NK (2010) Proteoglycans in health and adisease: novel roles for proteoglycan in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 93
    Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC & Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 24492457.
  • 94
    Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J & Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610617.
  • 95
    Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 1332613333.
  • 96
    Purushothaman A, Chen L, Yang Y & Sanderson RD (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 3262832636.
  • 97
    Manon-Jensen T, Itoh Y & Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 38763889.
  • 98
    Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B et al. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 20412048.
  • 99
    Peterson SB & Liu J (2010) Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem 285, 1450414513.
  • 100
    Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G et al. (2004) Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Biol Chem 47, 838848.
  • 101
    Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R & Vlodavsky I (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280, 1210312113.
  • 102
    Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L & Massague J (2009) Tumor self-seeding by circulating cancer cells. Cell 139, 13151326.
  • 103
    Leung CT & Brugge JS (2009) Tumor self-seeding: bidirectional flow of tumor cells. Cell 139, 12261228.
  • 104
    Joyce JA, Freeman C, Meyer-Morse N, Parish CR & Hanahan D (2005) A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24, 40374051.
  • 105
    Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I & Pappo O (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 157, 11671175.
  • 106
    Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N & Vlodavsky I (2009) Heparanase expression by Barrett’s epithelium and during esophageal carcinoma progression. Mod Pathol 22, 15481554.
  • 107
    Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP & Yang SM (2008) HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10, 977986.
  • 108
    Tang XD, Liang GP, Li C, Wan Y, Chen T, Chen L, Yu ST, Xiong Z, Fang DC, Wang GZ et al. (2010) Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice. Cancer Immunol Immunother 59, 10411047.
  • 109
    Tang XD, Wan Y, Chen L, Chen T, Yu ST, Xiong Z, Fang DC, Liang GP & Yang SM (2008) H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. Cancer Res 68, 15291537.
  • 110
    Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D et al. (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119, 33113321.
  • 111
    Schuetz F, Ehlert K, Ge Y, Schneeweiss A, Rom J, Inzkirweli N, Sohn C, Schirrmacher V & Beckhove P (2009) Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58, 887900.
  • 112
    Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I & Nagler A (2007) Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21, 22962303.
  • 113
    Ostrovsky O, Korostishevsky M, Shafat I, Mayorov M, Ilan N, Vlodavsky I & Nagler A (2009) Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J Leukoc Biol 86, 445455.
  • 114
    Ostrovsky O, Shimoni A, Rand A, Vlodavsky I & Nagler A (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115, 23192328.